Merck & Co Inc
NYSE: MRK
$114.99
-$0.64 (-0.6%)
Real Time Data Delayed 15 Min.
MRK Articles
All three major US stock indexes opened higher this morning, and spent the rest of the day bouncing around the neutral line. The reports from retailers on same-store sales in January were mixed, but...
Published:
Last Updated:
Merck & Company, Inc. (NYSE: MRK) is trading up after its earnings report. With a high dividend yield of 4.4%, many investors are watching this despite a stance of little to no real growth...
Published:
Last Updated:
Earnings season is still upon us. There are going to be many big earnings reports Thursday and we would consider Thursday as the climax for the companies reporting their normal fourth quarter...
Published:
Last Updated:
Pfizer, Inc. (NYSE: PFE) looks good on the surface on its earnings report for the fourth quarter, but the company’s guidance may be getting in the way a bit. The drug giant turned in results of...
Published:
Last Updated:
The tide of patent expirations that is washing over big pharmaceutical houses is cresting now and investors have begun looking forward to how these companies will deal with some sharp blows to their...
Published:
Last Updated:
US markets opened up slightly this morning and have maintained a slight positive tone for most of the day. Today marks the unofficial beginning of another earnings season, with Alcoa kicking things...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms this Monday morning. Akamai Technologies, Inc. (NASDAQ: AKAM) Cut to...
Published:
Last Updated:
For several years it has been the case that Amgen Inc. (NASDAQ: AMGN) was considered a biotech though it had at least some of the same problems of Big Pharma players like Pfizer Inc. (NYSE: PFE)...
Published:
Last Updated:
As each new year replaces the prior year, 24/7 Wall St. looks at the individual targets on all 30 Dow Jones Industrial Average price targets from Wall Street analysts to come up with a peak price for...
Published:
Last Updated:
The lineup of the Dogs of the Dow, simply the ten highest dividend yield stocks of the thirty Dow Jones Industrial Average components, appears to be undergoing a bit of change for 2012. There is a...
Published:
Last Updated:
We recently gave a full review of the DJIA components we expect to raise their dividend payouts in the weeks and months ahead. Among those we expect to raise the dividend is Pfizer Inc. (NYSE:...
Published:
Last Updated:
AuthorDendreon Corporation (NASDAQ: DNDN) is supposed to be the king of prostate cancer with its PROVENGE treatment. Unfortunately, PROVENGE sales ran slower than expected after the FDA took...
Published:
Last Updated: